Cancers, Vol. 11, Pages 1681: Targeting STAT3 in Cancer with Nucleotide Therapeutics

Cancers, Vol. 11, Pages 1681: Targeting STAT3 in Cancer with Nucleotide Therapeutics Cancers doi: 10.3390/cancers11111681 Authors: Yue-Ting K. Lau Malini Ramaiyer Daniel E. Johnson Jennifer R. Grandis Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an “undruggable” target for therapy; thus, much research has focused on targeting upstream pathways to reduce the expression or phosphorylation/activation of STAT3 in tumor cells. Recently, however, novel approaches have been developed to directly inhibit STAT3 in human cancers, in the hope of reducing the survival and proliferation of tumor cells. Several of these agents are nucleic acid-based, including the antisense molecule AZD9150, CpG-coupled STAT3 siRNA, G-quartet oligodeoxynucleotides (GQ-ODNs), and STAT3 decoys. While the AZD9150 and CpG-STAT3 siRNA interfere with STAT3 expression, STAT3 decoys and GQ-ODNs target constitutively activated STAT3 and modulate its ability to bind to target genes. Both STAT3 decoy and AZD9150 have advanced to clinical testing in humans. Here we will review the current understanding of the structures, mechanisms, and potential clinical utilities of the nucleic acid-based STAT3 inhibitors.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research